Subscribe To

Price Alert Latest News Economic Calendar News

KNSA / Kiniksa Pharmaceuticals (KNSA) CEO Sanj Patel on Q1 2022 Results - Earnings Call Transcript

Kiniksa Pharmaceuticals (NASDAQ:KNSA ) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Rachel Frank - Head of IR Sanj Patel - CEO and Chairman Ross Moat - Chief Commercial officer Mark Ragosa - CFO John Paolini - Chief Medical Officer Eben Tessari - COO Conference Call Participants Anupam Rama - JPMorgan. Paul Choi - Goldman Sachs David Nierengarten - Wedbush Securities Alexandria Hammond - Geoff Meacham Liisa Bayko - Evercore ISI Operator Good day, and thank you for standing by. Read More

Demo Live Account See Partner Details

Content Topics

Kiniksa

Pharmaceuticals

KNSA

Sanj

Patel

2022

Results

knsa

Earnings

Transcript

Stock

Posted: May 7 2022, 16:12

Author Name: Seeking Alpha

KNSA News

By Seeking Alpha
October 31, 2023

Kiniksa Pharmaceuticals Ltd (KNSA) Q3 2023 Earnings Call Transcript

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Rachel Frank - Associate

By Zacks Investment Research
October 31, 2023

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18.

By Zacks Investment Research
July 25, 2023

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.16.

By Seeking Alpha
July 19, 2023

Kiniksa Pharmaceuticals: Autoimmune Therapy Offers Attractive Prospects At Current Price

Innovations in the drug lineup, including ARCALYST, KPL-404, and Mavrilimumab, showcase Kiniksa's dedication to targeting challenging autoimmune and i

By GlobeNewsWire
July 15, 2023

Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023

HAMILTON, Bermuda, July 18, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call

By Seeking Alpha
May 6, 2023

Kiniksa Pharmaceuticals, Ltd. (KNSA) Q1 2023 Earnings Call Transcript

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q1 2023 Earnings Conference Call May 2, 2023 8:30 AM ET Company Participants Rachel Frank - Head of Inves

By GlobeNewsWire
May 1, 2023

Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023

HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call a

By InvestorPlace
April 5, 2023

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, th

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.